ArticlePathology oncology research : POR2002
CD44 variant exons in leukemia and lymphoma.
Article in Pathology oncology research : POR, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 36 citations in OpenAlex.
- Alternative splicing discriminates molecular subtypes and has prognostic impact in diffuse large B-cell lymphoma.Blood cancer journal · 2017Trial
- ABO Blood Group and the Risk and Prognosis of Lymphoma.Journal of inflammation research · 2023Review
- Article
- Characterization and Functional Analysis of CD44v6.CAR T Cells Endowed with a New Low-Affinity Nerve Growth Factor Receptor-Based Spacer.Human gene therapy · 2021Article
- Article
- CD44 splice variant (CD44v3) promotes progression of urothelial carcinoma of bladder through Akt/ERK/STAT3 pathways: novel therapeutic approach.Journal of cancer research and clinical oncology · 2019Article
- Recent advances in hyaluronic acid-decorated nanocarriers for targeted cancer therapy.Drug discovery today · 2017Review
- CD44 as a potential diagnostic tumor marker.Saudi medical journal · 2015Review
- CD44 standard and CD44v10 isoform expression on leukemia cells distinctly influences niche embedding of hematopoietic stem cells.Journal of hematology & oncology · 2014Article
- Role of CD44 expression in non-tumor tissue on intrahepatic recurrence of hepatocellular carcinoma.International journal of clinical oncology · 2013Article
- Hepatocyte nuclear factor (HNF)-1β and its physiological importance in endometriosis.Biomedical reports · 2013Review
- LRP-1--CD44, a new cell surface complex regulating tumor cell adhesion.Molecular and cellular biology · 2012Article
- Evaluation of some biochemical markers as prognostic factors in malignant lymphoma.International journal of health sciences · 2011Article
- CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?Nature reviews. Cancer · 2011Review
- CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway.PloS one · 2011Article
- Epithelial hyaluronic acid and CD44v6 are mutually involved in invasion of colorectal adenocarcinomas and linked to patient prognosis.Virchows Archiv : an international journal of pathology · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD44 is a cell surface glycoprotein expressed on different cell types that functions in lymphocyte activation and homing, extracellular matrix adhesion and cellular migration. CD44 is encoded by a single gene composed of at least 20 exons. The standard CD44 protein (CD44S or CD44H) is the hematopoietic form of CD44 in lymphoid cells. Variant isoforms (designated from v1 to v10) are formed by addition of new exons to the extracellular domain. High levels of CD44v6 expression has been observed in some tumors and are associated with metastatic spread. The aim of the present study was to investigate and evaluate expression of the CD44v6 and v6-containing variants as a possible marker in chronic myeloid leukemia and lymphoma by reverse transcription-polymerase chain reaction. CD44 exon v6 was detected in all patients and all individuals in the control group. CD44v6-v10 mRNA was observed in 25 patients but in none of the subjects in the control group. CD44v6/v9-10, CD44v6-v7, CD44v6/v10 transcripts were detected in 11, 6, and 2 patients, respectively. CD44v6-7/v9-10 transcripts were not observed in either the patients or the healthy individuals. We conclude that CD44v6-v10 expression may be associated with hematologic malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.